Epigenetic-based combinatorial resveratrol and pterostilbene alters DNA damage response by affecting SIRT1 and DNMT enzyme expression, including SIRT1-dependent γ-H2AX and telomerase regulation in triple-negative breast cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Kala, Rishabh ^a   Shah, Harsh N ^a   Martin, Samantha L ^a   Tollefsbol, Trygve O ^a,b,c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apoptosis; Breast cancer cells; Combination; DNMTs; Epigenetics; Genomic stability; SIRT1; Telomerase; H2AX

Indexed keywords

DNA METHYLTRANSFERASE; HISTONE DEACETYLASE 3; HISTONE H2AX; PTEROSTILBENE; RESVERATROL; SIRTUIN 1; TELOMERASE; ANTINEOPLASTIC AGENT; DNA (CYTOSINE 5) METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HISTONE; STILBENE DERIVATIVE;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CASE REPORT; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG MECHANISM; ENZYME REGULATION; EPIGENETICS; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; MIDDLE AGED; PROTEIN EXPRESSION; S PHASE CELL CYCLE CHECKPOINT; TRIPLE NEGATIVE BREAST CANCER; CELL CYCLE CHECKPOINT; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG POTENTIATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC EPIGENESIS; GENETICS; METABOLISM; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME ACTIVATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HISTONES; HUMANS; RECEPTOR, ERBB-2; SIRTUIN 1; STILBENES; TELOMERASE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84959143809     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1693-z     Document Type: Article

References (44)

1. Cancer facts & statistics 2015 http://www.cancer.org/research/cancerfactsstatistics/
2. Buchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, et al. Variety in vegetable and fruit consumption and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011;128:2971-9.
3. Gonzalez CA, Travier N, Lujan-Barroso L, Castellsague X, Bosch FX, Roura E, et al. Dietary factors and in situ and invasive cervical cancer risk in the European prospective investigation into cancer and nutrition study. Int J Cancer. 2011;129:449-59.
4. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer. 2005;41:834-45.
5. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6:107-16.
6. Zhu WG, Otterson GA. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents. 2003;3:187-99.
7. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3:415-28.
8. Saldanha SN, Kala R, Tollefsbol TO. Molecular mechanisms for inhibition of colon cancer cells by combined epigenetic-modulating epigallocatechin gallate and sodium butyrate. Exp Cell Res. 2014;324:40-53.
9. Meeran SM, Patel SN, Chan TH, Tollefsbol TO. A novel prodrug of epigallocatechin-3-gallate: differential epigenetic hTERT repression in human breast cancer cells. Cancer Prev Res (Phila). 2011;4:1243-54.
10. Meeran SM, Patel SN, Tollefsbol TO. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One. 2010;5, e11457.
11. Rajendran P, Ho E, Williams DE, Dashwood RH. Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetics. 2011;3:4.
12. Kala R. Li Y. Potential of Resveratrol in Inhibiting Cancer and Slowing Aging J Nutr Food Sci: Tollefsbol TO; 2012.
13. Mirza S, Sharma G, Parshad R, Gupta SD, Pandya P, Ralhan R. Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J Breast Cancer. 2013;16:23-31.
14. Gracia A, Elcoroaristizabal X, Fernández-Quintela A, et al. Fatty acid synthase methylation levels in adipose tissue: effects of an obesogenic diet and phenol compounds. Genes & Nutrition. 2014;9(4):411.
15. Li Y, Yuan YY, Meeran SM, Tollefsbol TO. Synergistic epigenetic reactivation of estrogen receptor-alpha (ERalpha) by combined green tea polyphenol and histone deacetylase inhibitor in ERalpha-negative breast cancer cells. Mol Cancer. 2010;9:274.
16. Kala R, Peek GW, Hardy TM, Tollefsbol TO. MicroRNAs: an emerging science in cancer epigenetics. J Clin Bioinforma. 2013;3:6.
17. Liu T, Liu PY, Marshall GM. The critical role of the class III histone deacetylase SIRT1 in cancer. Cancer Res. 2009;69:1702-5.
18. Stunkel W, Campbell RM. Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen. 2011;16:1153-69.
19. Zhang B, Chen J, Cheng AS, Ko BC. Depletion of sirtuin 1 (SIRT1) leads to epigenetic modifications of telomerase (TERT) gene in hepatocellular carcinoma cells. PLoS One. 2014;9, e84931.
20. Yamashita S, Ogawa K, Ikei T, Fujiki T, Katakura Y. FOXO3a potentiates hTERT gene expression by activating c-MYC and extends the replicative life-span of human fibroblast. PLoS One. 2014;9, e101864.
21. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci. 2009;5:147-52.
22. Ford J, Jiang M, Milner J. Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res. 2005;65:10457-63.
23. O'Hagan HM, Mohammad HP, Baylin SB. Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet. 2008;4, e1000155.
24. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet. 2006;2, e40.
25. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, et al. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer. 2004;41:117-24.
26. Khan S, Kumagai T, Vora J, Bose N, Sehgal I, Koeffler PH, et al. PTEN promoter is methylated in a proportion of invasive breast cancers. Int J Cancer. 2004;112:407-10.
27. Li Y, Tollefsbol TO. Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Curr Med Chem. 2010;17:2141-51.
28. d'Adda di Fagagna F, Teo SH, Jackson SP. Functional links between telomeres and proteins of the DNA-damage response. Genes Dev. 2004;18:1781-99.
29. Ahmed A, Tollefsbol TO. Telomerase, telomerase inhibition, and cancer. J Anti Aging Med. 2003;6:315-25.
30. Compusyn software for drug cominbations for general dose-effect analysis, and users guide combosyn unicorp http://www.combosyn.com
31. Chen H, Landen CN, Li Y, Alvarez RD, Tollefsbol TO. Epigallocatechin gallate and sulforaphane combination treatment induce apoptosis in paclitaxel-resistant ovarian cancer cells through hTERT and Bcl-2 down-regulation. Exp Cell Res. 2013;319:697-706.
32. Bonner WM, Redon CE, Dickey JS, Nakamura AJ, Sedelnikova OA, Solier S, et al. GammaH2AX and cancer. Nat Rev Cancer. 2008;8:957-67.
33. Howells LM, Moiseeva EP, Neal CP, Foreman BE, Andreadi CK, Sun YY, et al. Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals. Acta Pharmacol Sin. 2007;28:1274-304.
34. Estrela JM, Ortega A, Mena S, Rodriguez ML, Asensi M. Pterostilbene:Biomedical applicatons. Crit Rev Clin Lab Sci. 2013;50(3):65-78.
35. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res. 2009;7:4-13.
36. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010;363:1938-48.
37. Mikstacka R, Rimando AM, Ignatowicz E. Antioxidant effect of trans-resveratrol, pterostilbene, quercetin and their combinations in human erythrocytes in vitro. Plant Foods Hum Nutr. 2010;65:57-63.
38. Podhorecka M, Skladanowski A, Bozko P. H2AX Phosphorylation: Its Role in DNA Damage Response and Cancer Therapy. J Nucleic Acids. 2010;2010.
39. De Bonis ML, Ortega S, Blasco MA. SIRT1 Is Necessary for Proficient Telomere Elongation and Genomic Stability of Induced Pluripotent Stem Cells. Stem Cell Reports. 2014;2(5):690-706.
40. Nakamura AJ, Chiang YJ, Hathcock KS, Horikawa I, Sedelnikova OA, Hodes RJ, et al. Both telomeric and non-telomeric DNA damage are determinants of mammalian cellular senescence. Epigenetics Chromatin. 2008;1:6.
41. Love WK, Deangelis JT, Berletch JB, Phipps SM, Andrews LG, Brouillette WJ, et al. The Novel Retinoid, 9cUAB30, Inhibits Telomerase and Induces Apoptosis in HL60 Cells. Transl Oncol. 2008;1:148-52.
42. Holt SE, Wright WE, Shay JW. Regulation of telomerase activity in immortal cell lines. Mol Cell Biol. 1996;16:2932-9.
43. Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 2004;279:2273-80.
44. Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, et al. DNA Damage Cellular Stress Responses: MicroRNA-138 Modulates DNA Famage Response by Repressing Histone H2AX Expression. Mol Cancer Res. 2011;9:1100-11.